AbbVie revenue
AbbVie's revenue was $61.16bn in fiscal 2025, up 8.6% on the year before. Since fiscal 2011 ($17.44bn) it has grown at a compound 9.4% a year. Over the last twelve months it was $66.01bn.
Revenue history
| Fiscal year | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.4 | 18.4 | 18.8 | 20.0 | 22.9 | 25.6 | 28.2 | 32.8 | 33.3 | 45.8 | 56.2 | 58.1 | 54.3 | 56.3 | 61.2 | 66.0 |
| Growth on the year before | — | +5.4% | +2.2% | +6.2% | +14.5% | +12.2% | +10.1% | +16.1% | +1.6% | +37.7% | +22.7% | +3.3% | −6.4% | +3.7% | +8.6% | — |
| Gross profit | — | — | — | — | — | 19.8 | 21.2 | 25.0 | 25.8 | 30.4 | 38.8 | 40.6 | 33.9 | 39.4 | 43.0 | 48.7 |
| Gross margin | — | — | — | — | — | 77.3% | 75.0% | 76.4% | 77.6% | 66.4% | 69.0% | 70.0% | 62.4% | 70.0% | 70.2% | 73.7% |
Where the revenue comes from
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $46.6B | 76.2% | ▲ 8.3% |
| Other Countries | $5.8B | 9.4% | ▲ 5.7% |
| Germany | $1.7B | 2.8% | ▲ 18.6% |
| Japan | $1.3B | 2.1% | ▲ 13.5% |
| Canada | $1.2B | 2.0% | ▲ 12.3% |
| China | $1B | 1.6% | ▲ 9.7% |
| France | $806M | 1.3% | ▲ 3.9% |
| United Kingdom | $626M | 1.0% | ▲ 19.9% |
| ES | $609M | 1.0% | ▲ 15.3% |
| IT | $580M | 0.9% | ▲ 13.5% |
| Brazil | $478M | 0.8% | ▲ 3.0% |
| Australia | $459M | 0.8% | ▼ 0.9% |
From AbbVie's 10-K filed February 20, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| AbbVie | $66.01bn | 10.7% | 6.2% |
| Amgen | $38.09bn | 9.1% | 12.7% |
| Gilead Sciences | $30.99bn | 6.5% | 4.2% |
| Regeneron Pharmaceuticals | $16.90bn | 18.6% | 8.9% |
| Vertex Pharmaceuticals | $12.59bn | 10.2% | 9.8% |
| Biogen | $10.30bn | 2.3% | 1.0% |
Compare with peers
- Amgen revenue
- Gilead Sciences revenue
- Regeneron Pharmaceuticals revenue
- Vertex Pharmaceuticals revenue
- Biogen revenue
Head to head: ABBV vs AMGNABBV vs GILDABBV vs REGN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies